Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544562 | 0.93 | HSD11B1 (0.63) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL393656 | 0.81 | HSD11B1 (0.52) | HSD11B1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL6378605 | 0.78 | ALDH1A1 (0.50) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL13544827 | 0.78 | HSD11B1 (0.61) | HSD11B1ALDH1A1SMN1; SMN2HPGDEPHX1 | |
| SCHEMBL2871721 | 0.78 | ALDH1A1 (0.74) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL3421776 | 0.78 | ALDH1A1 (0.74) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL98282 | 0.78 | ALDH1A1 (0.74) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL10602483 | 0.78 | ALDH1A1 (0.74) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL7410366 | 0.77 | MAPK1 (0.59) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 | |
| SCHEMBL7407166 | 0.77 | MAPK1 (0.59) | HSD11B1ALDH1A1MAPK1SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497287-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2231589-B1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8314128-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101791-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2231589-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076399-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | HSD11B1 974/4885ALDH1A1 902/4885MAPK1 1046/4885 |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | HSD11B1 974/4885ALDH1A1 902/4885MAPK1 1046/4885 |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | HSD11B1 974/4885ALDH1A1 902/4885MAPK1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.